Ozempic side effects — common and unusual effects you should know
01 Mar
Ozempic (semaglutide) is one of the world’s most prescribed GLP-1 drugs, with millions of users worldwide. With the explosive use, the knowledge of side effects has also grown — from the well-known gastrointestinal problems to phenomena such as “Ozempic face” and questions about alcohol. We go through what the research and clinical experience shows about Ozempic’s side effect profile, what you can concretely do to manage the problems and when you should seek medical help.
Common side effects — focus on the gastrointestinal tract
The absolute most common side effects of Ozempic are linked to the gastrointestinal tract. Semaglutide slows gastric emptying and affects bowel movements, causing a range of discomforts that most users experience during the ramp-up phase.
Nausea is the most commonly reported side effect — about 20% of patients in the SUSTAIN trials experienced it, most of whom described the discomfort as mild to moderate. Nausea is most common in the first few days after each dose increase and tends to subside within one to two weeks. Eating smaller portions, avoiding fatty and strongly spiced foods and choosing cold or room-temperature dishes over hot ones can significantly reduce the discomfort. Some patients have good experience of taking their injection in the evening, so that the worst nausea passes during the night.
Diarrhea affects about 9% of users and is usually transient. Constipation, which may seem paradoxical in combination with diarrhea, occurs in approximately 5–6% and is due to altered gastric emptying. Fluid intake and fiber-rich foods help with both conditions, albeit in different directions. Vomiting is reported in approximately 5–9% and abdominal pain in 5–7%, both most commonly during dose escalation.
Practical advice during the escalation
Most gastrointestinal side effects subside after the body gets used to a given dose. The standard escalation for Ozempic is: 0.25 mg for four weeks, then 0.5 mg for four weeks, and finally 1 mg as a maintenance dose. If the symptoms are troublesome on a dose increase, there is nothing wrong with staying on the lower dose for an extra week or two before moving on — discuss this with your prescriber. “Pushing through” severe side effects often leads to patients discontinuing treatment prematurely, which is counterproductive.
Ozempic face — what is behind the phenomenon?
“Ozempic face” is not a medical term but a term that arose in social media and media reporting. It describes the aged, sunken face shape that some people develop after significant weight loss with semaglutide. The phenomenon is neither unique to Ozempic nor even to GLP-1 drugs — it occurs in all rapid and severe weight loss, regardless of method.
The mechanism behind Ozempic face is simple to understand: the face contains fat deposits that give volume and contour, especially around the cheeks, jawline and around the eyes. With significant weight loss, these fat stores decrease, and the skin — which does not shrink as fast as the underlying fat tissue — loses its support. The result is a looser, more sunken face shape that can give an older impression. Elderly patients are hit harder because the skin’s elasticity decreases with age and the ability to recover from volume loss is impaired.
The degree of Ozempic face directly correlates with the amount of body weight lost. A person who loses 5% of their body weight rarely notices a difference in their face. At 15-20% weight loss, which is common with Wegovy and Mounjaro, the changes become more apparent. This explains why the phenomenon is so strongly associated with GLP-1 drugs in particular — they simply provide more weight loss than previously available methods.
What can you do about it? Strength training and adequate protein intake (at least 1.2–1.6 grams per kilogram of body weight) help preserve muscle mass in the body, but unfortunately do not directly affect facial fat. Dermatological treatments such as hyaluronic acid fillers can restore volume to the face, but it is a cosmetic measure that does not address the underlying cause. The most realistic strategy is to accept that rapid weight loss always entails certain aesthetic changes and that these often partially improve over time when the skin has time to adapt.
Ozempic and alcohol — why caution is advised
The combination of Ozempic and alcohol is one of the most common questions among new users, and there are several reasons for caution — although alcohol is not an absolute contraindication.
Semaglutide lowers blood sugar. Alcohol does the same, especially when consumed on an empty stomach. The combination can cause unexpectedly low blood sugar (hypoglycaemia), with symptoms such as dizziness, sweating, tremors and, in extreme cases, unconsciousness. The risk is greatest for patients who are already taking other hypoglycemic drugs in parallel with Ozempic.
The delayed gastric emptying that semaglutide causes also affects how the body handles alcohol. Alcohol stays longer in the stomach, which can intensify the nausea that is already common during treatment. Several users report that their alcohol tolerance has decreased significantly after starting Ozempic — that they feel more heavily intoxicated with smaller amounts and that hangovers are worse.
From a caloric perspective, there is another aspect: alcohol contains 7 kcal per gram and offers zero nutritional value. With a reduced total caloric intake — which is the whole purpose of GLP-1 treatment — the empty calories of alcohol take their place from nutritious food that the body needs to maintain muscle mass and organ health.
Our recommendation: avoid alcohol completely during the escalation phase. Once you have stabilized on your maintenance dose and the gastrointestinal distress has subsided, moderate consumption can work for most people. A glass or two of wine with dinner doesn’t have to be problematic, but never drink on an empty stomach and be aware that your tolerance is likely to have changed.
Serious side effects — when should you seek care?
The serious side effects of Ozempic are uncommon but important to know. Pancreatitis (inflammation of the pancreas) occurs in rare cases and requires immediate medical assessment. The symptoms are severe, persistent abdominal pain that radiates to the back, often in combination with vomiting. If you suspect pancreatitis — discontinue Ozempic and contact healthcare the same day.
Gallbladder problems, including gallstones, occur with increased frequency with rapid weight loss regardless of method. Semaglutide may further increase this risk. Symptoms such as sudden, intense pain in the upper right part of the abdomen, especially after fattier meals, should be investigated.
Altered vision may occur in patients with existing diabetic retinopathy. If you have diabetes and notice vision changes during treatment, you should contact an ophthalmologist. This is especially true for rapid blood sugar improvements in patients with advanced retinopathy — not for the average user without eye problems.
In 2025, the EMA (European Medicines Agency) added a warning about the eye disease NAION (non-arteritic anterior ischemic optic neuropathy) to the semaglutide product information. The risk is assessed as very low, but symptoms such as sudden loss of vision in one eye should always be urgently investigated.
Thyroid cancer: in animal studies in rodents, semaglutide has caused thyroid tumors. Whether this risk applies to humans has not been established, but Ozempic should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2 syndrome. Contact healthcare if symptoms such as a lump or swelling in the throat, difficulty swallowing or persistent hoarseness.
Side effects in perspective — risk versus benefit
The list of side effects may seem daunting, but it’s worth putting it in perspective. The serious side effects are rare — pancreatitis affects less than 1% and NAION even fewer. The usual gastrointestinal side effects are in most cases transient and manageable.
Obesity itself carries significant health risks: cardiovascular disease, type 2 diabetes, sleep apnea, joint wear and tear and several forms of cancer. A weight loss of 10–15% significantly reduces these risks. For most patients with clinically significant excess weight, the benefit of the treatment outweighs the risks of the side effects.
The most important thing you can do is to be informed, follow the de-escalation schedule, stay in touch with your prescriber and report unusual symptoms early. GLP-1 drugs are powerful tools — and like all powerful tools, they work best when used with knowledge and respect. An overview of injectable weight loss drugs can provide additional perspective if you are considering switching preparations.
.entry-content